Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in egfr mutation test in patients with advanced lung adenocarcinoma

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Liu, Dan ^a   Lu, Yachao ^b   Hu, Zhenli ^a   Wu, Ning ^a   Nie, Xiaomeng ^a   Xia, Yang ^a   Han, Yiping ^a   Li, Qiang ^a   Zhu, Guanshan ^b   Bai, Chong ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; EGFR GENE; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MALE; MALIGNANT PLEURA EFFUSION; METASTATIC PLEURAL TUMOR TISSUE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; ONCOGENE; OUTCOME ASSESSMENT; SENSITIVITY AND SPECIFICITY; SUPERNATANT; TISSUE CHARACTERIZATION; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PLEURAL EFFUSION, MALIGNANT; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84896526995     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089946     Document Type: Article

References (22)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139. (Pubitemid 38637993)
4. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500. (Pubitemid 38720929)
5. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, et al. (2006) A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn 8: 335-341. (Pubitemid 44063810)
6. Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A (2008) High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 8: 142.
7. Kawada I, Soejima K, Watanabe H, Nakachi I, Yasuda H, et al. (2008) An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients. J Thorac Oncol 3: 1096-1103.
8. Jian G, Songwen Z, Ling Z, Qinfang D, Jie Z, et al. (2010) Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol 136: 1341-1347.
9. Soh J, Toyooka S, Aoe K, Asano H, Ichihara S, et al. (2006) Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer 119: 2353-2358. (Pubitemid 44546955)
10. Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, et al. (2006) EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer 95: 1390-1395. (Pubitemid 44760091)
11. Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, et al. (2006) High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci 97: 642-648. (Pubitemid 44056613)
12. Wu SG, Gow CH, Yu CJ, Chang YL, Yang CH, et al. (2008) Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J 32: 924-930.
13. Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37: 360-363. (Pubitemid 40656185)
14. Schiller JH (2001) Current standards of care in small-cell and non-small-cell lung cancer. Oncology 61 Suppl 1: 3-13.
15. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181.
16. Jiang SX, Yamashita K, Yamamoto M, Piao CJ, Umezawa A, et al. (2008) EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance. Int J Cancer 123: 2480-2486.
17. Canto A, Ferrer G, Romagosa V, Moya J, Bernat R (1985) Lung cancer and pleural effusion. Clinical significance and study of pleural metastatic locations. Chest 87: 649-652.
18. Sekine I, Sumi M, Saijo N (2008) Local control of regional and metastatic lesions and indication for systemic chemotherapy in patients with non-small cell lung cancer. Oncologist 13 Suppl 1: 21-27.
19. Hung MS, Lin CK, Leu SW, Wu MY, Tsai YH, et al. (2006) Epidermal growth factor receptor mutations in cells from non-small cell lung cancer malignant pleural effusions. Chang Gung Med J 29: 373-379.
20. Zhang X, Zhao Y, Wang M, Yap WS, Chang AY (2008) Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer. Lung Cancer 60: 175-182. (Pubitemid 351609150)
21. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K (2008) Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 99: 929-935. (Pubitemid 351997594)
22. Nakano H, Soda H, Takasu M, Tomonaga N, Yamaguchi H, et al. (2008) Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule. Lung Cancer 60: 136-140..